Literature DB >> 8519667

Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).

M Ciomei1, W Pastori, L Capolongo, C Geroni, G Melegaro, G Pennella, M Grandi.   

Abstract

Resistance to FCE 24517 is not related to the emergence of any of the most frequently observed phenotypes. We have found that two resistant cell lines (L1210/24517 murine leukaemia and LoVo/24517 human colon adenocarcinoma) present congenital modifications in tyrosyl phosphatase and kinase activities. Moreover, the cytotoxic activity of FCE 24517 is increased in combination with a tyrosine phosphatase inhibitor and decreased in combination with protein kinase inhibitors, this being in agreement with the hypothesis that the activity of this drug is strictly dependent on the presence of tyrosine phosphorylated protein(s).

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8519667      PMCID： PMC2034097          DOI： 10.1038/bjc.1995.537

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  13 in total

1.  Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line.

Authors:  M T Bütler; A Ziemiecki; B Groner; R R Friis
Journal:  Eur J Biochem       Date:  1989-11-06

Review 2.  The biochemistry of P-glycoprotein-mediated multidrug resistance.

Authors:  J A Endicott; V Ling
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

Review 3.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  M M Gottesman
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

4.  Differences in the nuclear matrix phosphoproteins of a wild-type and nitrogen mustard-resistant rat breast carcinoma cell line.

Authors:  B C Moy; K D Tew
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

5.  Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.

Authors:  F M Arcamone; F Animati; B Barbieri; E Configliacchi; R D'Alessio; C Geroni; F C Giuliani; E Lazzari; M Menozzi; N Mongelli
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

6.  Selective DNA interaction of the novel distamycin derivative FCE 24517.

Authors:  M Broggini; E Erba; M Ponti; D Ballinari; C Geroni; F Spreafico; M D'Incalci
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Characterization of the major protein-tyrosine-phosphatases of human placenta.

Authors:  N K Tonks; C D Diltz; E H Fischer
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

8.  Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.

Authors:  C Geroni; E Pesenti; G Tagliabue; D Ballinari; N Mongelli; M Broggini; E Erba; M D'Incalci; F Spreafico; M Grandi
Journal:  Int J Cancer       Date:  1993-01-21       Impact factor: 7.396

9.  Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents.

Authors:  G Tagliabue; A Pifferi; G Balconi; E Mascellani; C Geroni; M D'Incalci; P Ubezio
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

10.  Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR.

Authors:  M Streuli; N X Krueger; T Thai; M Tang; H Saito
Journal:  EMBO J       Date:  1990-08       Impact factor: 11.598
View more
  1 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.